Seo Jung-jin Celltrion

Bio & Pharma Celltrion unveils cancer medicine to expand new drug pipelines

South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...

Business & Politics Trump Jr. to visit Seoul next week to meet Korean business leaders

Donald Trump Jr., the eldest son of the US President Donald Trump, is set to visit Seoul next week and meet with Korean business leaders grappling w...

Bio & Pharma Celltrion expands footprint in Latin America with flagship oncology drugs

South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...

Bio & Pharma Celltrion wins Australian approval for eye, bone disease biosimilars

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

Leadership & Management Naver to build sovereign AI, says founder Lee after return

South Korea’s No. 1 internet portal operator Naver Corp. will build strong sovereign artificial intelligence to fight the growing dominance of...

Bio & Pharma Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...

Shareholder value Celltrion to cancel $140 mn in treasury shares, stock up

South Korea’s leading biosimilar drug developer Celltrion Inc. announced on Friday a plan to cancel $140 million worth of treasury shares to i...

Bio & Pharma Samsung, Celltrion lead biosimilar market in Europe, US

Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz in the antibody biosim...

Bio & Pharma Celltrion wins EU approval for autoimmune disease treatment Avtozma

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

Automobiles Hyundai Motor launches future strategy division overseeing M&As

Hyundai Motor Group has created a future business strategy division that serves as a control tower for the automotive group’s expansion into n...

Earnings Naver founder to return as board chair; 2024 earnings solid

Lee Hae-jin, the founder of South Korea’s No. 1 internet portal operator Naver Corp., is set to return to the company to lead the board amid t...

Bio & Pharma Celltrion’s Vegzelma: Most-prescribed cancer treatment in Europe

South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...

IPOs Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut

SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...

Bio & Pharma Korean drugmakers control more than half of European biosimilar market

South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar...

Bio & Pharma Celltrion obtains approval of Steqeyma from FDA

South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...

Bio & Pharma Celltrion BioSolutions launched to venture into CDMO

Celltrion Inc. on Tuesday launched its contract development and manufacturing organization unit Celltrion BioSolutions Co. in its foray into the CDM...

Bio & Pharma Celltrion’s 4 new biosimilars win EU approval recommendation

Celltrion Inc. is one step closer to commercializing its four new biosimilars in Europe after a committee of the European Medicines Agency (EMA) rec...

Markets Celltrion to allot cash, stock dividend at once

South Korea’s biosimilar maker Celltrion Inc. on Friday announced a plan to allot cash and stock dividends simultaneously. The company wi...

Korean food BTS Jin to enter liquor business

BTS Jin plans to enter Korean traditional liquor business with Baek Jong-won, founder and CEO of The Born Korea Co., the entertainment industry sour...

Korean chipmakers Samsung foundry ‘relief pitcher’ Han Jin-man vows to improve 2-nm yields

Samsung Electronics Co.'s new contract chipmaking business chief said on Monday he will go all-in to improve the company’s advanced 2-nanomete...

Bio & Pharma Celltrion gets approval of Omlyclo in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma an...

Shareholder value Celltrion to retire $400 mn treasury stock in January

South Korea’s biosimilar maker Celltrion Inc. on Wednesday announced a plan to retire about a quarter of its treasury stock worth 563 billion ...

Airlines Korean Air-Asiana merger to spur M&A among budget carriers

Korean Air Lines Co.'s anticipated acquisition of Asiana Airlines Inc. is expected to spur domestic budget carriers to seek mergers, with the two do...

Bio & Pharma Celltrion to break ground on CDMO plant in 2025: Chairman Seo

South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (...

Executive reshuffles Samsung reshuffles top brass; Co-CEO to control memory business

Samsung Electronics Co., the world’s No. 1 memory chipmaker, reshuffled its leadership on Wednesday in a sweeping move as it faces an uph...

Bio & Pharma Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug

Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...

Bio & Pharma Celltrion to acquire additional $72 mn in treasury shares

South Korea's Celltrion Inc. announced on Thursday that it decided to repurchase additional treasury shares worth 100 billion won ($71.6 million).Fr...

Bio & Pharma Celltrion acquires Swiss pharmaceutical distributor iQone

South Korea's Celltrion Inc. said on Friday that it completed its acquisition of iQone Healthcare Switzerland, a Swiss pharmaceutical distributor, t...

Korean stock market MSCI Korea Index adds Hyundai Rotem

MSCI announced on Wednesday that South Korea's Hyundai Rotem Co. will be added to the Morgan Stanley Capital International (MSCI) Korea Index. ...

Earnings HYBE Q3 profit down; foresees better 2025 after BTS’ military discharges

HYBE Co., the K-pop behemoth behind BTS, suffered a double-digit profit fall in the third quarter amid an ongoing feud with Min Hee-jin, the creativ...